BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association Technical Review on the Role of the Gastroenterologist in the Management of Esophageal Carcinoma. Gastroenterology 2005;128:1471-505. [DOI: 10.1053/j.gastro.2005.03.077] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang QL, Ness-Jensen E, Santoni G, Xie SH, Lagergren J. Development and Validation of a Risk Prediction Model for Esophageal Squamous Cell Carcinoma Using Cohort Studies. Am J Gastroenterol 2021;116:683-91. [PMID: 33982937 DOI: 10.14309/ajg.0000000000001094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Fountoulakis A, Souglakos J, Vini L, Douridas GN, Koumarianou A, Kountourakis P, Agalianos C, Alexandrou A, Dervenis C, Gourtsoyianni S, Gouvas N, Kalogeridi M, Levidou G, Liakakos T, Sgouros J, Sgouros SN, Triantopoulou C, Xynos E. Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer. Updates Surg 2019;71:599-624. [DOI: 10.1007/s13304-019-00696-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Batra R, Malhotra GK, Singh S, Are C. Managing Squamous Cell Esophageal Cancer. Surg Clin North Am 2019;99:529-41. [PMID: 31047040 DOI: 10.1016/j.suc.2019.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
4 Kahn A, Crowell MD, Fleischer DE. Reducing the risk of esophageal squamous cell carcinoma: out with the old; in with the new. Gastrointest Endosc 2019;89:733-5. [PMID: 30902201 DOI: 10.1016/j.gie.2018.12.017] [Reference Citation Analysis]
5 Grupp K, Uzunoglu FG, Melling N, Hofmann B, El Gammal AT, Grotelüschen R, Heumann A, Bellon E, Reeh M, Wolters-Eisfeld G, Ghabdan T, Nentwich M, Bachmann K, Bockhorn M, Bogoevski D, Izbicki JR, Kutup A. FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas. Sci Rep 2018;8:17370. [PMID: 30478420 DOI: 10.1038/s41598-018-35459-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Codipilly DC, Qin Y, Dawsey SM, Kisiel J, Topazian M, Ahlquist D, Iyer PG. Screening for esophageal squamous cell carcinoma: recent advances. Gastrointest Endosc 2018;88:413-26. [PMID: 29709526 DOI: 10.1016/j.gie.2018.04.2352] [Cited by in Crossref: 52] [Cited by in F6Publishing: 79] [Article Influence: 13.0] [Reference Citation Analysis]
7 Bohle W, Kasper M, Zoller WG. Prognostic relevance of serial endoscopic ultrasound after chemoradiation in esophageal cancer. Diseases of the Esophagus 2017;30:1-8. [DOI: 10.1093/dote/dox065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Bohle W, Kasper M, Zoller WG. Different accuracy of endosonographic tumor staging after neoadjuvant chemotherapy and chemoradiotherapy in esophageal cancer. Surg Endosc 2016;30:2922-8. [PMID: 26487231 DOI: 10.1007/s00464-015-4578-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
9 Ganz RA, Mitlyng B, Leon S. The case for ablating nondysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;80:866-872. [PMID: 25436398 DOI: 10.1016/j.gie.2014.06.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
10 Varghese TK Jr, Hofstetter WL, Rizk NP, Low DE, Darling GE, Watson TJ, Mitchell JD, Krasna MJ. The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg. 2013;96:346-356. [PMID: 23752201 DOI: 10.1016/j.athoracsur.2013.02.069] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
11 Patil DT, Bennett AE, Mahajan D, Bronner MP. Distinguishing Barrett gastric foveolar dysplasia from reactive cardiac mucosa in gastroesophageal reflux disease. Hum Pathol 2013;44:1146-53. [PMID: 23332925 DOI: 10.1016/j.humpath.2012.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yang S, Wu S, Huang Y, Shao Y, Chen XY, Xian L, Zheng J, Wen Y, Chen X, Li H, Yang C. Screening for oesophageal cancer. Cochrane Database Syst Rev 2012;12:CD007883. [PMID: 23235651 DOI: 10.1002/14651858.CD007883.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
13 Orlicka K, Maynard S, Bouin M. Unusual presentation of a metastatic esophageal carcinoma. Case Rep Gastroenterol 2012;6:273-8. [PMID: 22679417 DOI: 10.1159/000339211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Didden P, Spaander MC, Wijnhoven BP, Kuipers EJ, Bruno MJ. Improving the quality of pretreatment staging in patients with esophageal carcinoma - a fast track study. Acta Oncol 2012;51:362-7. [PMID: 22023087 DOI: 10.3109/0284186X.2011.626449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Fang D, Das KM, Cao W, Malhotra U, Triadafilopoulos G, Najarian RM, Hardie LJ, Lightdale CJ, Beales IL, Felix VN. Barrett’s esophagus: progression to adenocarcinoma and markers. Ann N Y Acad Sci. 2011;1232:210-229. [PMID: 21950815 DOI: 10.1111/j.1749-6632.2011.06053.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
16 Gupta N, Bansal A, Wani SB, Gaddam S, Rastogi A, Sharma P. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011;74:610-624.e2. [PMID: 21741639 DOI: 10.1016/j.gie.2011.05.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
17 Gonzalez S, Yu WM, Smith MS, Slack KN, Rotterdam H, Abrams JA, Lightdale CJ. Randomized comparison of 3 different-sized biopsy forceps for quality of sampling in Barrett’s esophagus. Gastrointest Endosc. 2010;72:935-940. [PMID: 21034895 DOI: 10.1016/j.gie.2010.07.035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
18 Katona BW, Falk GW. Barrett’s esophagus surveillance: When, how often, does it work? Gastrointest Endosc Clin N Am. 2011;21:9-24. [PMID: 21112494 DOI: 10.1016/j.giec.2010.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kamal A, Vaezi MF. Diagnosis and initial management of gastroesophageal complications. Best Pract Res Clin Gastroenterol 2010;24:799-820. [PMID: 21126695 DOI: 10.1016/j.bpg.2010.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
20 Scholl S, Dellon ES, Shaheen NJ. Treatment of GERD and Proton Pump Inhibitor Use in the Elderly: Practical Approaches and Frequently Asked Questions. American Journal of Gastroenterology 2011;106:386-92. [DOI: 10.1038/ajg.2010.409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
21 Allison H, Banchs MA, Bonis PA, Guelrud M. Long-term remission of nondysplastic Barrett's esophagus after multipolar electrocoagulation ablation: report of 139 patients with 10 years of follow-up. Gastrointest Endosc 2011;73:651-8. [PMID: 21111417 DOI: 10.1016/j.gie.2010.09.037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
22 Chennat J, Ferguson MK. Endoscopic interventions in Barrett's esophagus: Do the dollars make sense? Gastrointest Endosc Clin N Am 2011;21:145-53. [PMID: 21112504 DOI: 10.1016/j.giec.2010.09.004] [Reference Citation Analysis]
23 Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2010;32:1222-1227. [PMID: 20955441 DOI: 10.1111/j.1365-2036.2010.04471.x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 112] [Article Influence: 10.3] [Reference Citation Analysis]
24 Wong T, Tian J, Nagar AB. Barrett‘s surveillance identifies patients with early esophageal adenocarcinoma. Am J Med. 2010;123:462-467. [PMID: 20399324 DOI: 10.1016/j.amjmed.2009.10.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
25 Pace F, Bazzoli F, Fiocca R, Di Mario F, Savarino V, Vigneri S, Vakil N. The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2009;21:394-408. [PMID: 19262401 DOI: 10.1097/meg.0b013e32830a70e2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
26 Bujanda L, Gil I, Sarasqueta C, Hijona E, Cosme A, Elorza JL, Asensio JI, Larburu S, Lacasta A, Arévalo S, Mínguez J. [Clinicopathological characteristics and survival outcome of esophageal cancer. Results from a series of 200 patients]. Med Clin (Barc) 2009;133:689-93. [PMID: 19767034 DOI: 10.1016/j.medcli.2009.04.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
27 Tomizawa Y, Wang KK. Screening, surveillance, and prevention for esophageal cancer. Gastroenterol Clin North Am 2009;38:59-73, viii. [PMID: 19327567 DOI: 10.1016/j.gtc.2009.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
28 Shaheen NJ, Palmer LB. Improving Screening Practices for Barrett's Esophagus. Surgical Oncology Clinics of North America 2009;18:423-37. [DOI: 10.1016/j.soc.2009.03.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
29 Dumot JA, Vargo JJ 2nd, Falk GW, Frey L, Lopez R, Rice TW. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc. 2009;70:635-644. [PMID: 19559428 DOI: 10.1016/j.gie.2009.02.006] [Cited by in Crossref: 107] [Cited by in F6Publishing: 103] [Article Influence: 8.2] [Reference Citation Analysis]
30 Mandal RV, Forcione DG, Brugge WR, Nishioka NS, Mino-kenudson M, Lauwers GY. Effect of Tumor Characteristics and Duplication of the Muscularis Mucosae on the Endoscopic Staging of Superficial Barrett Esophagus-related Neoplasia. American Journal of Surgical Pathology 2009;33:620-5. [DOI: 10.1097/pas.0b013e31818d632f] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
31 Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136:2101-2114.e1-6. [PMID: 19272389 DOI: 10.1053/j.gastro.2009.02.062] [Cited by in Crossref: 140] [Cited by in F6Publishing: 128] [Article Influence: 10.8] [Reference Citation Analysis]
32 Voutilainen M. Epidemiological trends in oesophageal cancer in the Nordic countries. Scand J Gastroenterol. 2008;43:323-327. [PMID: 18938769 DOI: 10.1080/17489530701699720] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
33 Armstrong D. Should patients with Barrett's oesophagus be kept under surveillance? The case for. Best Pract Res Clin Gastroenterol 2008;22:721-39. [PMID: 18656826 DOI: 10.1016/j.bpg.2008.03.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
34 Twine CP, Roberts SA, Barry JD, Oliphant H, Morgan MA, Blackshaw GRJ, Lewis WG. Prospective comparison of the perceived preoperative computed tomographic, endosonographic and histopathological stage of oesophageal cancer related to body mass indices. Eur Radiol 2009;19:935-40. [DOI: 10.1007/s00330-008-1208-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
35 Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825-37. [PMID: 18371146 DOI: 10.1111/j.1572-0241.2007.01773.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 105] [Article Influence: 7.1] [Reference Citation Analysis]
36 Ponce M, Garrigues V, Ortiz V, Ponce J. Trastornos de la deglución: un reto para el gastroenterólogo. Gastroenterología y Hepatología 2007;30:487-97. [DOI: 10.1157/13110504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
37 Mino-kenudson M, Hull MJ, Brown I, Muzikansky A, Srivastava A, Glickman J, Park D, Zuckerberg L, Misdraji J, Odze RD, Lauwers GY. EMR for Barrett's esophagus–related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointestinal Endoscopy 2007;66:660-6. [DOI: 10.1016/j.gie.2007.02.063] [Cited by in Crossref: 92] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
38 Beales IL, Ogunwobi O, Cameron E, El-Amin K, Mutungi G, Wilkinson M. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett’s oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. BMC Cancer. 2007;7:97. [PMID: 17559672 DOI: 10.1186/1471-2407-7-97] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
39 Lu F, Chen H, Zhou C, Liu S, Guo M, Chen P, Zhuang H, Xie D, Wu S. T-type Ca2+ channel expression in human esophageal carcinomas: a functional role in proliferation. Cell Calcium. 2008;43:49-58. [PMID: 17532042 DOI: 10.1016/j.ceca.2007.03.006] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
40 Jones DB. ROLE OF ENDOSCOPIC ULTRASOUND IN STAGING UPPER GASTROINTESTINAL CANCERS. ANZ J Surg 2007;77:166-72. [DOI: 10.1111/j.1445-2197.2006.04000.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
41 Carneiro F, Chaves P. Pathologic Risk Factors of Adenocarcinoma of the Gastric Cardia and Gastroesophageal Junction. Surgical Oncology Clinics of North America 2006;15:697-714. [DOI: 10.1016/j.soc.2006.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
42 Brankley SM, Wang KK, Harwood AR, Miller DV, Legator MS, Lutzke LS, Kipp BR, Morrison LE, Halling KC. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett’s esophagus. J Mol Diagn. 2006;8:260-267. [PMID: 16645214 DOI: 10.2353/jmoldx.2006.050118] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
43 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20; quiz 1943. [PMID: 16928254 DOI: 10.1111/j.1572-0241.2006.00630.x] [Cited by in Crossref: 2308] [Cited by in F6Publishing: 1938] [Article Influence: 144.3] [Reference Citation Analysis]
44 Schlansky B, Dimarino AJ, Loren D, Infantolino A, Kowalski T, Cohen S. A survey of oesophageal cancer: pathology, stage and clinical presentation. Aliment Pharmacol Ther. 2006;23:587-593. [PMID: 16480397 DOI: 10.1111/j.1365-2036.2006.02782.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
45 Wolfsen H, Canto M, Etemad B, Greenwald B, Gress F, Schembre D, Muthusamy VR, Ribeiro A, Sharma V, Ginsberg G. Bare fiber photodynamic therapy using porfimer sodium for esophageal disease. Photodiagnosis and Photodynamic Therapy 2006;3:87-92. [DOI: 10.1016/j.pdpdt.2006.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
46 Younes M, Georgakis GV, Rahmani M, Beer D, Younes A. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. European Journal of Cancer 2006;42:542-7. [DOI: 10.1016/j.ejca.2005.11.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]